News

Abstract #1245 studies were designed to study advanced NSCLC chemotherapy-naive patients treated with ramucirumab in combination with first-line ALIMTA (pemetrexed for injection)/platinum-based chemotherapy while Abstract#1287 studied patients treated

Under the contract, Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s Conjumab-A, aiming on age-related macular degeneration (AMD) with potential

Somatoprim, which is currently in phase I of clinical development, is a new molecular entity somatostatin analogue which is proved in treating Acromegaly, carcinoid tumours, and Cushing’s disease,

Folic acid solution for injection, which is used as a pre-injection for etarfolatide radiodiagnostic imaging agent, is intended for use in selecting patients for whom treatment with folate

Pierre Fabre has discovered and jointly developed Levomilnacipran with the support of Forest Laboratories under a licensing agreement in the US and Canada. Forest Laboratories has submitted the

According to IMS Health, the Singulair granules had sales of nearly $61m in the US market for recent twelve months ending July 2012. The company has released the

The manufacturing project is part of recently received funding from the National Institute of Allergy and Infectious Diseases (NIAID) to offer preclinical development and cGMP manufacturing support for

The patent covers the potential of the resin-formulated drug in reducing or eliminating the choking hazard, which is associated with conventional liquid formulations of benzonatate. Alitair president and

Transdermal tirofiban, a non-peptide, reversible GP IIb/IIIa receptor antagonist, has the ability to dissolve and directly prevent formation of platelet aggregates (blood clots) in the blood vessels. In